These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30127467)

  • 1. Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
    Chaulagain CP; Sprague KA; Pilichowska M; Cowan J; Klein AK; Kaul E; Miller KB
    Bone Marrow Transplant; 2019 Apr; 54(4):560-566. PubMed ID: 30127467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Baron F; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation.
    Cheon J; Lee YJ; Jo JC; Kweon K; Koh S; Min YJ; Park SH; Lee SH; Kim HJ; Choi Y
    Support Care Cancer; 2021 Feb; 29(2):975-986. PubMed ID: 32556712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
    Nagler A; Or R; Naparstek E; Varadi G; Slavin S
    Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.
    Singh N; Loren AW
    Clin Chest Med; 2017 Dec; 38(4):575-593. PubMed ID: 29128011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes.
    Mawardi H; Elad S; Correa ME; Stevenson K; Woo SB; Almazrooa S; Haddad R; Antin JH; Soiffer R; Treister N
    Bone Marrow Transplant; 2011 Jun; 46(6):884-91. PubMed ID: 21460866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation].
    Luo RM; Da WM; Hu B; Si YJ; Zhang XM; Du ZL; Liu QH; Wang Y; Yue Y; Chen W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1047-52. PubMed ID: 25130826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.
    Bergeron A
    Clin Chest Med; 2017 Jun; 38(2):249-262. PubMed ID: 28477637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
    Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):264-71. PubMed ID: 24274982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft failure after allogeneic hematopoietic stem cell transplantation.
    Ozdemir ZN; Civriz Bozdağ S
    Transfus Apher Sci; 2018 Apr; 57(2):163-167. PubMed ID: 29724627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
    Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC
    Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation.
    Ragbourne SC; Crook MA
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):340-346. PubMed ID: 28622958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.
    Chen MH; Chang PM; Li WY; Hsiao LT; Hong YC; Liu CY; Gau JP; Liu JH; Chen PM; Chiou TJ; Tzeng CH
    Bone Marrow Transplant; 2011 Apr; 46(4):567-72. PubMed ID: 20622906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.